Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 735659, 5 pages
http://dx.doi.org/10.1155/2014/735659
Research Article

Isocitrate Dehydrogenase-1 Mutations as Prognostic Biomarker in Glioblastoma Multiforme Patients in West Bohemia

1Department of Neurology, Faculty of Medicine in Pilsen, Charles University in Prague, Husova 3, 301 66 Pilsen, Czech Republic
2Faculty Hospital in Pilsen, Alej Svobody 80, 304 60 Pilsen, Czech Republic
3Department of Histology and Embryology and Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, Husova 3, 301 66 Pilsen, Czech Republic
4Department of Biology, Faculty of Medicine in Pilsen, Charles University in Prague, Husova 3, 301 66 Pilsen, Czech Republic
5Central Immunoanalytical Laboratory, Faculty Hospital in Pilsen, Dr. E. Benese 13, 305 99 Pilsen, Czech Republic

Received 30 September 2013; Accepted 18 December 2013; Published 9 January 2014

Academic Editor: Franco M. Buonaguro

Copyright © 2014 J. Polivka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Krex, B. Klink, C. Hartmann et al., “Long-term survival with glioblastoma multiforme,” Brain, vol. 130, no. 10, pp. 2596–2606, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. T. A. Dolecek, J. M. Propp, N. E. Stroup, and C. Kruchko, “CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009,” Neuro-Oncology, vol. 14, supplement 5, pp. v1–v49, 2012. View at Google Scholar
  3. J. Polivka Jr., J. Polivka, V. Rohan, O. Topolcan, and J. Ferda, “New molecularly targeted therapies for glioblastoma multiforme,” Anticancer Research, vol. 32, pp. 2935–2946, 2012. View at Google Scholar
  4. D. W. Parsons, S. Jones, X. Zhang et al., “An integrated genomic analysis of human glioblastoma multiforme,” Science, vol. 321, no. 5897, pp. 1807–1812, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. R. A. Cairns and T. W. Mak, “Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities,” Cancer Discovery, vol. 3, pp. 730–741, 2013. View at Google Scholar
  6. M. Sanson, Y. Marie, S. Paris et al., “Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas,” Journal of Clinical Oncology, vol. 27, no. 25, pp. 4150–4154, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Yan, D. W. Parsons, G. Jin et al., “IDH1 and IDH2 mutations in gliomas,” The New England Journal of Medicine, vol. 360, no. 8, pp. 765–773, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. G. P. Dunn, O. C. Andronesi, and D. P. Cahill, “From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma,” Neurosurgical Focus, vol. 34, article E2, 2013. View at Google Scholar
  9. C. Hartmann, J. Meyer, J. Balss et al., “Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas,” Acta Neuropathologica, vol. 118, no. 4, pp. 469–474, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Turcan, D. Rohle, A. Goenka et al., “IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype,” Nature, vol. 483, no. 7390, pp. 479–483, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Hartmann, B. Hentschel, W. Wick et al., “Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas,” Acta Neuropathologica, vol. 120, no. 6, pp. 707–718, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Polivka, J. Polivka Jr., V. Rohan, and O. Topolcan, “Glioblastoma multiforme—a review of pathogenesis, biomarkers and therapeutic perspectives,” Česká a Slovenská Neurologie a Neurochirurgie, vol. 76, no. 109, pp. 575–583, 2013. View at Google Scholar
  13. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. S. A. Forbes, N. Bindal, S. Bamford et al., “COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer,” Nucleic Acids Research, vol. 39, no. 1, pp. D945–D950, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Dang, D. W. White, S. Gross et al., “Cancer-associated IDH1 mutations produce 2-hydroxyglutarate,” Nature, vol. 465, article 966, 2010. View at Publisher · View at Google Scholar
  16. C. Loenarz and C. J. Schofield, “Expanding chemical biology of 2-oxoglutarate oxygenases,” Nature Chemical Biology, vol. 4, no. 3, pp. 152–156, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Lu, P. S. Ward, G. S. Kapoor et al., “IDH mutation impairs histone demethylation and results in a block to cell differentiation,” Nature, vol. 483, no. 7390, pp. 474–478, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Ye, S. Ma, Y. Xiong, and K. L. Guan, “R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis,” Cancer Cell, vol. 23, pp. 274–276, 2013. View at Google Scholar
  19. M. Weiler and W. Wick, “Molecular predictors of outcome in low-grade glioma,” Current Opinion in Neurology, vol. 25, pp. 767–773, 2012. View at Google Scholar
  20. P. Zou, H. Xu, P. Chen et al., “IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis,” PLoS ONE, vol. 8, Article ID e68782, 2013. View at Google Scholar
  21. J. Kim and R. J. DeBerardinis, “Cancer. Silencing a metabolic oncogene,” Science, vol. 340, pp. 558–559, 2013. View at Google Scholar
  22. K. Ichimura, D. M. Pearson, S. Kocialkowski et al., “IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas,” Neuro-Oncology, vol. 11, no. 4, pp. 341–347, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. P. J. Killela, Z. J. Reitman, Y. Jiao et al., “TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, pp. 6021–6026, 2013. View at Google Scholar